BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Samsung Biologics secures deal to mass-produce Lilly's antibody treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : November 17, 2020, 16:33 | Updated : November 17, 2020, 16:33
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Samsung Biologics]


SEOUL -- Samsung Biologics, a leading bio company in South Korea, has secured a long-term contract to mass-produce COVID-19 antibody treatment developed by Eli Lilly and Company, an American pharmaceutical company, showing confidence in its experience in the successful initial production that followed a deal in May. Financial terms were not disclosed.

Samsung BioLogics said the company has strengthened cooperation with Lilly to produce and deliver the initial batch of pharmaceutical products that met good manufacturing practices, which are required in order to conform to the guidelines recommended by agencies that control authorization, licensing and sale. CEO Kim Tae-han pledged the quick and stable supply of COVID-19 treatments through cooperation with Lilly.

"Based on our goal to maximize customer satisfaction and our mission to speed up the end of COVID-19, we were able to produce high-quality treatments in the shortest period of time and provide them to Lilly," Kim said, referring to a contract manufacturing organization (CMO) in May. CMO serves other companies to provide comprehensive services from development through manufacturing.

A neutralizing antibody defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. In April, Samsung BioLogics clinched a deal worth $360 million to produce candidate materials being developed by Vir Biotechnology, an American clinical-stage immunology company. Vir agreed to transfer technology for the consignment production of candidate materials.

Vir's current development pipeline includes SARS-CoV-2 that causes COVID-19 and its proprietary monoclonal antibody platform technology will be used to identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the COVID-19 pandemic and future outbreaks.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Samsung Biologics develops new perfusion cultivation to reduce production time.
    Samsung Biologics develops new perfusion cultivation to redu…
  • .Samsung BioLogics makes $1.47 bln investment to build fourth plant.
    Samsung BioLogics makes $1.47 bln investment to build fourth…
  • .Samsung Biologics scores victory in patent suit against Lonza of Switzerland.
    Samsung Biologics scores victory in patent suit against Lonz…

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Hanwha Systems works with antenna manufacturer to develop on-the-move satellite communication termin…
  • Naver and Korean Air join hands to interlink services
  • Hyosung Heavy localizes medium-voltage direct current transmission system
  • Samsung Electronics develops new technology to improve 5G network performance
  • S. Korea to share know-how of biodegradable fishing net production with Kuwait
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view